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Abstract
 
The extent of human memory T cell proliferation, differentiation, and telomere erosion that
occurs after a single episode of immune challenge in vivo is unclear. To investigate this, we
injected tuberculin purified protein derivative (PPD) into the skin of immune individuals and
isolated responsive T cells from the site of antigenic challenge at different times. PPD-specific
CD4
 
 
 
 T cells proliferated and differentiated extensively in the skin during this secondary
response. Furthermore, significant telomere erosion occurred in specific T cells that respond
in the skin, but not in those that are found in the blood from the same individuals. Tissue fluid
obtained from the site of PPD challenge in the skin inhibited the induction of the enzyme
telomerase in T cells in vitro. Antibody inhibition studies indicated that type I interferon
(IFN), which was identified at high levels in the tissue fluid and by immunohistology, was
responsible in part for the telomerase inhibition. Furthermore, the addition of IFN-
 
 
 
 to
PPD-stimulated CD4
 
 
 
 T cells directly inhibited telomerase activity in vitro. Therefore, these
results suggest that the rate of telomere erosion in proliferating, antigen-specific CD4
 
 
 
 T cells
may be accelerated by type I IFN during a secondary response in vivo.
Key words: senescence • inﬂammation • differentiation • proliferation • cytokines
 
Introduction
 
The greater human longevity compared with that in mice
indicates that human T cell memory will have to be
maintained for much longer in vivo (1). This suggests that
the persistence of human memory T cell pools may be
subjected to additional constraints relative to animal systems.
The majority of expanded T cells that are generated during
an immune response are cleared by apoptosis to enable cel-
lular homeostasis to be achieved during immune resolution.
However, mechanisms that prevent the death of some cells
have to be engaged to enable memory T cells to persist (2).
The type I IFNs and cytokines that signal through the IL-2R
common 
 
 
 
-chain are two groups of mediators that can
induce  activated T cell survival (2–4). Paradoxically, the
antiapoptotic effects of these cytokines are also associated
with chronic T cell–mediated inflammation in diseases such
as rheumatoid arthritis and atopic eczema (5–7). Because this
does not occur during normal immune resolution, additional
control mechanisms that prevent excessive persistence of T
cells at the end of an immune response must also exist.
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It has been shown that the loss of replicative capacity due
to telomere erosion can also regulate memory T cell main-
tenance (8). Telomeres are repeating hexameric sequences
of DNA that are located at the ends of chromosomes (9).
Each cell division leads to the loss of 50–100 bp of telo-
meric DNA due to the inability of DNA polymerase to
fully replicate the ends of the chromosomes (10, 11). Al-
though the induction of the enzyme telomerase during a
primary response to antigen can compensate for telomere
loss in antigen-specific T cells in vivo (12–14), upon re-
peated stimulation, T cells lose the ability to induce this en-
zyme, resulting in telomere erosion (15). This leads even-
tually to cell cycle arrest and replicative senescence; this is a
mechanism that determines the residual replicative capacity
of proliferating T cells (16–18).
The lack of suitable models has restricted investigations
into mechanisms that regulate human memory T cells in
vivo. This work was designed to establish an experimental
system for the investigation of the kinetics of human mem-
ory T cell proliferation, differentiation, and telomere ero-
sion during a secondary response to characterize factors that
may regulate the persistence of these cells in situ. To do
this, we injected purified protein derivative (PPD) into the
skin of individuals who were immunized with Bacille Cal-
mette-Guerin (BCG) to induce a secondary CD4
 
 
 
 T cell
response, also known as the Mantoux test (MT). Respond-
ing T cells were isolated from skin suction blisters (SBs)
that were induced over these lesions at different times (19).
We found that there was considerable proliferation of
PPD-specific CD4
 
 
 
 T cells during the secondary response
in the skin and demonstrate that these cells differentiated to
a CD45RB
 
lo
 
 phenotype. Furthermore, we demonstrate for
the first time that telomere erosion occurs in specific mem-
ory CD4
 
 
 
 T cells during a secondary response in a non-
lymphoid site and that this results in part from inhibition of
telomerase in these cells by type I IFN in situ.
 
Materials and Methods
 
Volunteers. 
 
This work was approved by the Ethics Commit-
tee of the Royal Free Hospital. MT reactions were induced in
healthy BCG-vaccinated volunteers on the flexor aspect of fore-
arms by the intradermal injection of 0.1 ml of either 10 or 100
U/ml tuberculin PPD (Evans Vaccines Ltd.). Induration, palpa-
bility, and the change in erythema from baseline were measured
and scored on day 3 and at the time of sampling as described pre-
viously (20). The MTs were sampled by skin biopsy or skin SB at
an allotted time point between 0 and 19 d after PPD injection.
One SB was induced in each of 100 individuals, who responded
to the MT. In addition, for investigations into changes in T cell
clonal distribution and telomere length, pairs of blisters were in-
duced on 15 additional subjects that were harvested at two differ-
ent time points. The mean age of the volunteers was 36.5 yr
(10.4 
 
 
 
 SD). There was no significant difference in the median
ages of individuals studied at each time point (Kruskal-Wallis test,
P 
 
 
 
 0.99). In addition, there was no difference in the number of
males and females studied at each time point (
 
 
 
2
 
 test, P 
 
  
 
0.6).
 
Skin SBs. 
 
Skin SBs were induced by the application of a
negative pressure of 25–40 kPa (200–300 mmHg) below atmo-
spheric pressure via a suction chamber for 2–4 h using a clinical
suction pump (VP25; Eschmann) until a unilocular blister mea-
suring 10–15 mm in diameter was formed. SBs were raised over
the sites of PPD injection (MTs) or normal skin 18–24 h before
sampling to ensure maximum cell recovery. The blister fluid was
microcentrifuged at 650 
 
g
 
 for 4 min to pellet the cells present.
The pellet was resuspended in complete medium (RPMI 1640;
Invitrogen and Life Technologies) containing 10% human AB se-
rum, 100 U/ml penicillin, 100 
 
 
 
g/ml streptomycin, and 2 mM
 
l
 
-glutamine (all obtained from Sigma-Aldrich). Blister CD4
 
 
 
 T
cells were purified by negative selection. Blister cells were first
incubated with antibodies against CD8, CD14, CD16 (Beckman
Coulter), CD19, and glycophorin A (Beckman Coulter), and
these cells were added to plates coated with rabbit anti–mouse
immunoglobulins (DakoCytomation).
 
PBMC Preparation. 
 
Heparinized blood was collected from
the same individuals at the time of blister aspiration. PBMCs
were prepared by density centrifugation on Ficoll-Paque (Amer-
sham Biosciences). CD4
 
 
 
 T cells were isolated by positive or
negative selection using the VARIO MACS (Miltenyi Biotec).
CD45RO
 
 
 
 populations were isolated by positive selection.
 
Flow Cytometric Analysis. 
 
Four-parameter analysis of T cell
phenotype was performed on a FACSCalibur™ (Becton Dickin-
son) as described previously (21). Cells were enumerated after
staining with fluorochrome-conjugated CD3, CD4, CD8, and/
or Ki67 using TruCOUNT™ tubes (all obtained from Becton
Dickinson). Other reagents were used as follows: CD45RA-
FITC, IFN-
 
 
 
–APC, IFN-
 
 
 
–FITC, IL-2–FITC, and Ki67-FITC
(all obtained from Becton Dickinson); and CD4-PE, CD45RA-
PE, and CD45RB-FITC (all obtained from DakoCytomation).
 
Intracellular Cytokine Staining. 
 
SBs or PBMCs were stimu-
lated with 10 
 
 
 
g/ml PPD (Statens Serum Institut) or 1:1,000
dilution tetanus toxoid (Aventis Pasteur MSD Ltd.) and incu-
bated for 15 h at 37
 
 
 
C in a humidified 5% CO
 
2
 
 atmosphere. 5
 
 
 
g/ml brefeldin A (Sigma-Aldrich) was added after 2 h. Un-
stimulated controls were also included. The cells were fixed
and permeabilized (Fix & Perm
 
®
 
 Cell Permeabilisation Kit;
Caltag Laboratories) before staining for CD3, CD4, IL-2, and
IFN-
 
 
 
.
 
Measurement of Telomere Length by Flow Cytometric Detection of
Fluorescence In Situ Hybridization (Flow-FISH). 
 
Telomere length
of CD4
 
 
 
 T cells was measured using a modified two-color flow-
FISH protocol (21). The cells were stained with CD4-biotin
(Immunotech) followed by streptavidin-Cy3 (Cedarlane Labora-
tories Ltd.), after which samples were fixed and permeabilized
(Fix & Perm
 
®
 
 Cell Permeabilisation Kit; Caltag Laboratories).
After washing in hybridization buffer, cells were incubated with
0.75 
 
 
 
g/ml of the PNA telomeric (C
 
3
 
TA
 
2
 
)
 
3
 
 probe conjugated to
Cy5. Samples were heated for 10 min at 82
 
 
 
C, rapidly cooled on
ice, and hybridized for 1 h at room temperature in the dark. Sam-
ples were washed and analyzed immediately by flow cytometry.
Fluorescently labeled beads (DakoCytomation) were used to
standardize the cytometer settings. No probe controls were in-
cluded to allow for differences in background fluorescence be-
tween samples. In addition, two cryopreserved PBMC samples
with known telomere fluorescence were used as standards to en-
sure consistency of the results.
To measure telomere length of Ag-specific CD4
 
 
 
 cells, we
developed a three-color flow-FISH technique. SBs or PBMCs
were stimulated with PPD for 15 h as aforementioned. After sur-
face staining with CD4-biotin and streptavidin-Cy3, samples
were fixed, permeabilized, and stained with IFN-
 
 
 
–FITC before
hybridization with the telomeric probe. 
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Telomerase Activity. 
 
Telomerase activity was measured using
the telomeric repeat amplification protocol (TRAPeze Telomer-
ase Detection Kit; Intergen Company). In brief, telomerase
present in a test cell extract extends a template with telomeric re-
peats and, after PCR amplification, generates a ladder of products
with 6-bp increments starting at 50 nucleotides. Samples were
collected by the snap freezing of cells either recovered from
SBs or from in vitro cultures at various time points after PPD
injection or stimulation, respectively. Absolute numbers of
CD3
 
 
 
Ki67
 
 
 
 cells in each sample were enumerated using Tru-
count tubes and Ki67 analysis. PCR was performed with samples
adjusted to 500 Ki67
 
 
 
 T cells per reaction. The negative control
contains the PCR mix without cell extract, and the positive con-
trol contains an extract of a telomerase positive tumor cell line.
 
Type I IFN Inhibition Experiments.
 
To investigate the effect of
blister fluid on telomerase up-regulation in vitro, fresh day 3 blis-
ter fluid was added to 0.5 
 
 
 
g/ml PPD-stimulated PBMCs from
the same donor (50% final dilution). In addition, autologous se-
rum was also added to PPD-stimulated PBMCs as a control (25%
final dilution). To block the effects of type I IFN, anti-CD118
antibody (anti–IFN-
 
 
 
, receptor chain 2; Calbiochem) or isotype
control antibody (mouse IgG2a; Sigma-Aldrich) was added at 2.5
 
 
 
g/ml to samples cultured in the presence of MT blister fluid.
Samples for telomerase measurement were collected on day 3 af-
ter PPD stimulation, and proliferation was measured on day 5.
To investigate the direct inhibition of telomerase activity by type
I IFN in vitro, PPD-specific CD4 T cell lines generated from
normal donors were restimulated in the presence of various doses
of recombinant IFN-
 
 
 
 (subtype 2a; R&D systems) or Roferon, a
clinically used preparation of IFN-
 
 
 
 (subtype 2a; Roche Pharma-
ceuticals). After 4 d, the cells were assayed for telomerase activity.
Samples were adjusted to 500 Ki67
 
 
 
 T cells per reaction as afore-
mentioned.
 
Long-Term Cell Culture. 
 
Cells were isolated from blisters in-
duced 19 d after PPD challenge in vivo and restimulated with
PPD-pulsed, irradiated autologous PBMCs in vitro. Cell lines
were maintained in complete medium supplemented with 5 ng/
ml IL-2 and restimulated with 1 
 
 
 
g/ml PPD-pulsed autologous
irradiated PBMCs every 10–14 d. Fresh medium and IL-2 were
added every 3–4 d. Cell numbers and viability were quantified
with Tru-count tubes. Population doublings (PD) were calcu-
lated using the following equation: PD 
 
 
 
 log (number of cells
counted after expansion) 
 
 
 
 log (number of cells seeded)/log2.
 
Histological Analysis of Skin Biopsies. 
 
Frozen 6-
 
 
 
m sections of
skin biopsies were fixed and immunostained using indirect im-
munoperoxidase, double indirect immunofluorescence, indirect
alkaline phosphatase, and TUNEL methods as described previ-
ously (20). The number of positive cells was quantified by image
analysis using a circular 100-
 
 
 
m diameter circular frame centered
on the five largest perivascular infiltrates per section as described
previously (20). Unconjugated anti–IFN-
 
 
 
 antibody (C10F5;
murine IgG1) was purchased from Serotec Ltd.
 
Measurement of Type I IFN in Blister Fluids. 
 
The amount of
type I IFN in blister fluid was assayed by a standard antiviral assay
(22). The concentration of type I IFN was determined by com-
parison with a standard curve prepared from IFN-
 
 
 
 at known
concentrations (IFN-
 
 
 
–N1, Wellferon; GlaxoSmithKline).
 
Assessment of Clonality by Heteroduplex Analysis (HDA). 
 
The
clonal composition of purified CD4
 
 
 
 T cells isolated from blisters
at days 7 or 19 after PPD challenge in vivo or CD4
 
 
 
 T cells from
blood from the same volunteers was determined by comparing
the CDR3 region of different TCR V
 
 
 
 families. Blood CD4
 
 
 
 T
cells were collected at day 0 and cultured either with or without
PPD and autologous irradiated PBMCs for 7 d in vitro. PCR was
performed on 26 V
 
 
 
 families (V
 
  
 
1–24 including V
 
 
 
 5.1 and 5.2
and V
 
 
 
 13.1 and 13.2) using specific V
 
 
 
 and common C
 
 
 
 prim-
ers at each time point as described previously (23). Each sample
PCR was mixed with V
 
 
 
-matched carrier DNA, denatured, and
reannealed. The product was run on a 12% polyacrylamide gel,
which was blotted and hybridized with a probe to the external
C
 
 
 
 region of the carrier. The probe was detected using anti–
digoxigenin-AP Fab fragments and CDP-Star substrate (Roche
Diagnostics). Identical clones within PBMCs and CD4
 
 
 
 T cell
populations were detected as heteroduplex bands with identical
migration patterns (23). The presence of heteroduplices has been
shown previously to relate to the presence of an expanded clone
as determined by the sequencing of PCR product (23).
 
Results
 
A Human In Vivo Model of a Memory Immune Response.
 
Healthy individuals who had been vaccinated previously
against tuberculosis with BCG were selected for this analy-
sis. The MT was induced by the intradermal injection of
tuberculin PPD (Fig. 1 a). The clinical manifestation of this
response was measured in terms of the change in erythema,
size of induration, and palpability of the lesion, which
peaked at 3 d after PPD injection, confirming previous pa-
pers (Fig. 1 b and references 5, 20). A novel observation
was that the number of infiltrating T cells did not reach
maximal levels until 7 d after PPD injection (Fig. 1 b).
Therefore, the clinical and cellular peaks of this secondary
response are asynchronous.
We adapted the skin SB technique to isolate leukocytes
from the site of the MT at different times after PPD injec-
tion. Significantly higher numbers of leukocytes were ob-
tained from the site of PPD injection (mean, 339,000;
range, 5,000–1.5 
 
 
 
 10
 
6
 
) at all time points compared with
normal skin (mean, 50,830; range, 2,100–217,500; P 
 
 
 
0.0001). The maximum yield of cells in the SBs was found
between days 2–3 compared with subsequent time points of
the skin test reaction (P 
 
  
 
0.0001). However, no significant
differences in yield were observed between days 5 and 19.
Identical results were obtained when the yield was adjusted
to the number of leukocytes per microliter of blister fluid to
control for variations in blister size (unpublished data).
Lymphocytes constituted the majority of the leukocytes
in SBs (Fig. 1 c), and 
 
 
 
98% of these were CD3
 
 
 
 T cells
(not depicted). Other leukocytes found in the blister popu-
lations included CD68
 
 
 
 monocytes and macrophages as
well as smaller numbers of CD1a
 
 
 
 Langerhans cells and
DCs (unpublished data). The proportion of CD4
 
 
 
 T cells
increased significantly from 57.7 to 88% on days 3 and 19,
respectively, after antigenic challenge (Kruskal-Wallis test;
P 
 
  
 
0.0006), whereas expression in the peripheral blood
did not change significantly during this period (Fig. 1 d).
Greater than 95% of the CD4
 
 
 
 T cells that were harvested
from skin blisters or identified within biopsies were of the
CD45RA
 
 
 
 (CD45RO
 
 
 
) primed/memory phenotype as
compared with 50% of CD4
 
 
 
 T cells in the blood (see Fig.
4 a), supporting previous observations that the MT is a
CD4
 
 
 
 memory, T cell–mediated immune response (5, 20). 
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Specific CD4
 
 
 
T Cells Proliferate at the Site of Antigenic
Challenge.
 
We evaluated the proportion of antigen-spe-
cific CD4
 
 
 
 T cells that were isolated from the skin during
the MT by their ability to synthesize IFN-
 
 
 
 after restimu-
lation with PPD in vitro (Fig. 2 a). Minimal IFN-  was
synthesized when PPD was not added to the blister cells
or when the cells were stimulated with tetanus toxoid
(Fig. 2, a and b). Therefore, the cells that expressed IFN-
  were Ag-specific (PPD). We found a significant increase
in these cells after intradermal challenge with PPD (Fig. 2
b; Kruskal-Wallis test; P   0.0001). There was no in-
crease in Ag-specific CD4  T cells in the blood, and these
remained relatively constant at 0.5% of the CD4  T cell
pool throughout the course of the response (Fig. 2 b).
The maximum proportion of Ag-specific CD4  T cells
detected after antigen challenge (32% of total CD4  T
cells) was considerably higher than that predicted from
previous studies (0.5–2%; reference 24). The proportion
of CD8  Ag-specific T cells in the blisters did not in-
crease during the course of the response and was  1% at
all time points.
Next, we investigated whether proliferation of T cells in
situ contributed to the accumulation of Ag-specific CD4 
T cells after PPD injection. Tissue biopsies obtained from
the site of antigen injection at different times were immu-
nostained with the antibody to Ki67, which identifies cells in
all phases of the cell cycle (Fig. 2 c; reference 25). We
found that at day 7, at the time of maximal CD4  T cell
accumulation,  20% of CD4  T cells were in cycle (Fig.
2, c and d). Similar proportions of proliferating CD4  T
cells were identified by both immunohistochemistry in skin
sections and by flow cytometry of blister cells taken at dif-
ferent time points. However, Ki67  CD4  T cells were
not observed in blood at the same time points (unpublished
data), indicating that the increase of PPD-specific CD4  T
cells in the skin is mediated in part by proliferation of these
cells in situ. We also found that there was an accumulation
of apoptotic T cells during the course of the MT (Fig. 2 d).
This indicates the dynamic nature of the response with
both proliferation and death of CD4  T cells taking place
at the site of antigenic challenge in vivo.
We are confident that the SB protocol actually samples
cells that are responding in situ and not just those that are
migrating away for the following reasons. First, the phe-
notype of CD4  T cells in tissue sections and SBs was
identical (CD45RO CD45RA ). Second, the propor-
tions of CD4  T cells that were proliferating and the ki-
netics of proliferation were virtually identical when these
cells were investigated by histology or in the blister sam-
ples, indicating that we were investigating the same re-
sponding population (Fig. 2 d). Third, the yield of cells
obtained from blisters over the course of the aforemen-
tioned Mantoux reaction parallels the numbers of leuko-
cytes that were observed by histology at different times af-
ter PPD injection (20).
Our results highlight that there is significant T cell ac-
tivity long after the perceived clinical course of the skin
test reaction. This is because previous studies have not
generally sampled the skin beyond 4 d after antigen injec-
tion (19, 26). The continued T cell reactivity in the skin
of our system between days 7 and 19 probably reflects
both the continued presence of residual antigen and the
expansion of these cells by cytokines that are present in
situ (5, 20).
Figure 1. The Mantoux test (MT): a hu-
man in vivo model of a memory immune
response. Samples were collected between
0 and 19 d after PPD injection (a, left).
Skin biopsies were collected for immuno-
histochemistry, and the top right panel
shows a day-3 MT skin section with a
perivascular (PV) collection of CD3  T
cells (E and D denote the epidermis and
dermis, respectively; magnification, 20).
Cutaneous lymphocytes were isolated from
skin SBs that were induced over the sites of
PPD injection at different times (a, bottom
right). In panel b, the clinical score resulting
from PPD challenge was measured at the
time of sampling ( , left y axis), whereas
the number of T cells within dermal
perivascular infiltrates was determined by
indirect immunoperoxidase staining ( ,
right y axis). The mean   SEM of five ex-
periments per time point is shown. In
panel c, the percentage of granulocytes
(black bars), lymphocytes (gray bars), and
other leukocytes (white bars) isolated from
SBs raised at different time points after PPD
injection is shown. Leukocyte proportions
were determined by flow cytometry. The
mean   SEM for three to six experiments per time point is shown. The percentage of CD3  T cells expressing CD4 in the peripheral blood (black bars)
and blisters (white bars) during the course of the MT response was determined by flow cytometry (d). The mean   SEM for four to seven experiments
per time point is shown.Reed et al. 1437
The Same CD4  T Cell Clones Persist during the Course of
the MT. It was unclear how the turnover of CD4  T cells
at the site of PPD injection affected the clonal composition
of CD4  T cells during the course of the response. To as-
sess potential changes in the clonal distribution, we used
HDA (27). Unstimulated CD4  T cells from blood
showed a polyclonal smear after HDA (Fig. 3 a). However,
upon stimulation of these cells in vitro with PPD, clonal
bands were detected (Fig. 3 a). CD4  T cells isolated from
blisters on day 7 after PPD challenge showed a highly oli-
goclonal distribution (Fig. 3 a). Virtually all the clones
identified in the blister samples at day 7 were also found in
PPD-stimulated PBMCs from the same individuals (93–
96%), indicating that the clonal bands in blister samples
represented PPD-specific clones (Fig. 3 a). Of the clones
identified in stimulated blood cells, only 66% (range 44–
85%) were present in the skin at day 7, suggesting that not
all CD4  T clones that were found in blood could enter or
survive in the skin.
Next, we investigated the clonal relationship between
CD4  T cells that were isolated from pairs of skin blisters
in the same individuals that were induced over the sites of
PPD injection at days 7 and 19. We measured the total
number of clones that were found in 26 different V  fami-
lies. We identified 44   14 clonal bands on day 7 (mean  
SEM of four individuals) and 40   15 at day 19 (Fig. 3 b).
Clonality during the course of the PPD response remained
relatively stable with 80% of the clones (range 57–94%) that
were identified at day 19 also being present at day 7 (Fig. 3
b). The 20% of clones that were found on day 19, but that
were not observed on day 7, probably represented recently
expanded populations. Although 74% of clones that were
found at day 7 were also present at day 19, there were 26  
15% (range 9–43%) of clones that were not present, sug-
gesting that some clones are lost during the MT. Overall,
this points to a dynamic picture in which the vast majority
of PPD-specific clones in the skin are maintained during
Figure 2. Antigen-specific CD4  T cell
infiltration and proliferation in the skin during
the MT. PBMCs and blister cells were stim-
ulated with PPD, control antigen (tetanus
toxoid), or left unstimulated for 15 h in the
presence of brefeldin A. Representative dot
plots of intracellular IFN-  expression in
days 3 and 7 blister cells are shown (a). The
number in the top right quadrant of each
dot plot indicates the percentage of CD4 
T cells producing IFN- . (b) The propor-
tion of IFN- –secreting (PPD-specific)
CD4  T cells after PPD injection. The
graph illustrates intracellular IFN-  expres-
sion in PBMCs stimulated with PPD (gray
diamonds) and blister cells stimulated with
PPD (black squares) or tetanus toxoid
(white squares). The mean   SEM of 3–11
experiments performed at each time point is
shown. Proliferating CD4  T cells in skin
sections after PPD injection (c). Double
immunofluorescence staining shows CD4 
cells (green) and proliferating Ki67  cells
(red; magnification, 20), whereas double
positive Ki67 CD4  cells are shown in yel-
low. (d) The percentage of proliferating
Ki67  CD4  T cells in the skin after PPD
challenge was determined by flow cytometry using blister cells (gray bars) and by double immunofluorescence in skin sections (white bars). The pro-
portion of apoptotic (TUNEL ) T cells in the perivascular infiltrates of skin sections was determined by double immunofluorescence (diamonds and
dashed line). The mean   SEM of three to five experiments performed at each time point is shown.
Figure 3. Clonal analysis of CD4  T cells in the skin during the MT.
HDA of purified blood and blister CD4  T cells was performed for the
26 V  families (a). Unstimulated blood CD4  T cells (Unstim), blood
CD4  T cells stimulated with PPD in vitro for 7 d (PPD), and blister
CD4  T cells from a day 7 MT (Blister CD4) collected from the same
individual were compared. One representative V  family from one out
of five volunteers that were investigated is shown. Solid-line arrows indi-
cate clonal bands shared between PPD-stimulated blood CD4  T cells
and blister cells. Dashed-line arrows indicate clonal bands that are only
present in the PPD-stimulated blood CD4  T cells. HDA was performed
for 26 different V  families on purified blister CD4  T cells isolated from
paired MTs on days 7 and 19 (b). Arrows on the left of each gel indicate
clonal bands that are present in the blisters at both time points. Three
representative V  families from one out of four volunteers are shown.
The asterisks on each gel indicate the position of the carrier homoduplex.Telomerase Inhibition in Memory T Cells by Type I Interferon In Vivo 1438
the course of the immune response. However, some clonal
evolution also occurs that may be due to the proliferation,
apoptosis, and also migration of some specific CD4  T cells
in and out of the immune response in situ (Fig. 2 d).
CD4  T Cells Differentiate in the Skin during a Secondary
Response. We investigated CD45RB expression as an in-
dication of the extent of CD4  T cell differentiation in
situ. This molecule is highly expressed in CD45RA CD4 
naive T cells, but shows bimodal distribution on primed/
memory CD45RA RO  CD4  T cells (28). Memory
CD4  T cells that are CD45RBlow are more differentiated
and have shorter telomeres compared with those that are
CD45RBhigh cells (unpublished data).
During the course of the MT, virtually all the CD4  T
cells isolated from the skin were CD45RA CD45RO  in
contrast with the CD4  population from blood from the
same individuals, where many CD45RA  T cells were ob-
served (Fig. 4 a). When we compared CD45RB expression
on CD45RA CD45RO  (primed) CD4  T cells from
blood and blisters in the same individuals on days 3 and 7
during the induction and peak phases of the response, re-
spectively, no difference was observed (Fig. 4 b). However,
by day 19, a significantly greater number of CD4  T cells
from the skin showed low CD45RB expression compared
with equivalent populations from paired blood samples.
This indicated that primed Ag-specific CD4  T cells
undergo further differentiation in situ after PPD chal-
lenge (Fig. 4 b). To confirm this, we measured the telo-
mere length of CD4  T cells in the skin using flow-FISH
(21). Because all CD4  T cells in the skin blisters are
CD45RO , we compared their telomere lengths with
blood CD4 CD45RO  T cells. At day 7 after PPD injec-
tion, the telomere length of CD4  T cells in the SBs was
similar to that found in CD4 CD45RO  T cells from
blood samples in the same individuals (Fig. 4 c). However,
by day 19, the telomere length of CD4  T cells from the
skin was significantly shorter than the equivalent popula-
tion in blood, confirming that they were more differenti-
ated. The decrease in telomere mean fluorescence intensity
in blister samples observed at day 19 equates to the loss of
0.4 kb of telomeric DNA as determined using calibration
curves correlating telomere length (in kilobases) measured
by Southern blot analysis with the flow-FISH technique as
described previously (21).
We developed a three-color flow-FISH technique,
which involves gating on IFN-  CD4  T cells after short-
term ex vivo stimulation with PPD, followed by flow-
FISH staining for telomeres (Fig. 4 d). This technique
demonstrated that PPD-specific CD4  T cells at the site of
antigenic stimulation had shorter telomeres compared with
PPD-specific CD4  T cells from blood in the same indi-
viduals. Therefore, Ag-specific T cell proliferation and dif-
ferentiation occurs at the site of secondary immune chal-
lenge in the skin in humans (Fig. 4 d).
Telomerase Activity in the Skin. We investigated whether
telomere erosion in CD4  T cells after PPD stimulation in
Figure 4. Differentiation of
CD4  T cells in the skin during
the MT. Representative dot
plots of CD45RA and CD45RB
expression on blood (PB) and
suction blister (SB) CD4  T cells
on different days after PPD chal-
lenge (a). The dotted line defines
the gate between CD45RB high
and low expression. (b) The per-
centage of highly differentiated
CD4  memory T cells (defined
as CD45RA , CD45RBlo) in
the blood ( ) and skin blisters
( ) during the MT. The hori-
zontal line denotes the mean.
p-values were calculated using
the paired Student’s t test. The
telomere length of blood ( )
and skin ( ) CD4 CD45RO 
T cells was determined during
the MT (c). The telomere length
of CD4  T cells from blood and
SBs at days 7 and 19 after PPD
injection was determined by
two-color flow-FISH. The hor-
izontal line denotes the mean.
p-values were calculated using
the paired Student’s t test. The
telomere length of PPD-specific
blood and skin CD4  T cells 19 d
after MT induction was determined by three-color flow-FISH (d). The histogram shows the telomere length (mean fluorescence intensity [MFI]) of
PPD-specific (as defined by IFN-  production) CD4  T cells in the blood (shaded histogram) and blister (unshaded histogram). The data represent one
out of two experiments with identical results that were performed.Reed et al. 1439
vivo resulted from lack of telomerase induction in these
cells. At days 3 and 7 after PPD challenge, there was exten-
sive CD4  T cell cycling as 7.7   2.0% and 17.8   6.2%
of these cells, respectively, were Ki67 . The extent of cell
cycling was greater than that observed when CD4  T cells
from blood were stimulated by PPD in vitro for 3 and 7 d,
respectively (2.4   0.4% and 9.7   4.0% Ki67 ). Because
telomerase is only up-regulated in the activated proliferat-
ing population of T cells (29, 30), we standardized telomer-
ase assays to include an equivalent number of Ki67  T cells
in each sample. For the first time, this allowed a direct
comparison of the activity of this enzyme in cycling CD4 
T cells from both blood and blister at different times after
stimulation (30, 31). Telomerase activity was minimal in
cycling CD4  T cells that were isolated from the skin com-
pared with CD4  T cells from blood that were stimulated
by PPD in vitro (Fig. 5, a and b). This indicated that telo-
mere erosion in PPD-specific CD4  T cells was linked to
the lack of telomerase activity in these cells in vivo.
To determine if the lack of telomerase in Ag-specific
CD4  T cells was due either to inherent inability to induce
this enzyme or to active inhibition of this enzyme in situ,
we isolated blister cells 3 d after PPD challenge and investi-
gated their ability to up-regulate telomerase activity after
PPD stimulation in vitro (Fig. 5 c). As before, there was
very little telomerase activity in freshly isolated cycling blis-
ter T cells; however, there was a fivefold increase in telom-
erase when these cells were restimulated in vitro (Fig. 5 c).
This suggested that telomerase was actively inhibited in
situ, but that this inhibition was reversible. This was con-
firmed by inhibiting telomerase activity of PPD-stimulated
blood derived CD4  T cells in vitro, with blister fluid ob-
tained at day 3 from the site of PPD injection from the
same donor (Fig. 5 d).
Type I IFN within the MT Inhibits Telomerase Induction.
Our previous studies indicate that type I IFN (IFN-  and
IFN- ) can regulate the rate of differentiation of human T
cells (32). Together with reports that IFN-  can inhibit the
activity of telomerase in tumor cell lines in vitro (33), this
prompted us to determine whether this group of cytokines
was responsible for the inhibition of telomerase activity in
PPD-specific CD4  T cells in the skin in situ. By immuno-
histological analysis, we identified cells that expressed high
levels of IFN-  in the perivascular infiltrates of skin sec-
tions 3 d after PPD challenge (Fig. 6 a). High uniform lev-
els of expression were also detected in keratinocytes (Fig. 6
a). This was confirmed by measurement of peak concentra-
tions of type I IFN in SB fluid that was obtained at day 3
after PPD injection (Fig. 6 b). This coincided with the time
at which telomerase was greatest in CD4  T cells that were
PPD-stimulated in vitro, but absent from cycling CD4  T
cells in the skin (Fig. 5 b).
The telomerase activity of PPD-stimulated CD4  T cells
obtained from peripheral blood was much lower when these
cells were cultured with blister fluid from a day-3 MT rela-
tive to culture with autologous serum (Fig. 6 c). We added
an antibody directed to the second subunit of the type I IFN
receptor (anti–IFN-R2), which blocks the signaling by all
forms of type I IFN, to PPD stimulated T cells that were
cultured with day 3 blister fluid. An isotype control antibody
was also added to identical cultures. The IFN-R2 antibody
induced a fivefold enhancement of telomerase activity in
these cultures, whereas the addition of a control antibody
had little effect (Fig. 6 c). Furthermore, we showed that the
addition of clinically used preparations of IFN-  (Roferon)
or recombinant IFN-  at concentrations similar to that
found in blister fluid directly blocked the induction of
telomerase activity in PPD-stimulated T cells in a dose-
dependent manner in vitro (Fig. 6 d). In addition, IFN- 
could also block telomerase activity in PPD-stimulated T
cells (unpublished data). We do not rule out the possibility
that other members of the type I IFN family, such as limitin
(22, 34), or other factors may also contribute in part to tel-
omerase inhibition in the skin during a Mantoux reaction.
Figure 5. Low telomerase activity in CD4  T cells in the skin after
PPD stimulation in vivo. Telomerase activity in T cells isolated from SBs
after PPD injection in two different individuals on days 3 and 7 after PPD
injection (in vivo) and also from blood CD4  T cells from one individual
at different times after PPD stimulation in vitro (a). Telomerase activity
(total product generated) per 500 Ki67  proliferating T cells isolated from
MTs (b, white bars) and PBMCs stimulated in vitro with PPD (black
bars). The mean   SEM of three experiments is shown. Skin CD4  T
cells can up-regulate telomerase activity when stimulated with PPD in
vitro (c). T cells were isolated from day 3 MTs, and telomerase activity
was determined in T cells immediately upon isolation (Blister), whereas
the remaining cells were stimulated with PPD in vitro for 3 d (In vitro
re-stim). Data are representative of four experiments performed. The
negative control contains the PCR mix without cell extract, and the
positive control contains an extract of a telomerase-positive tumor cell
line. TSR8 denotes the internal quantitative control. Day 3 blister fluid
suppresses telomerase activity (d). PBMCs were stimulated with PPD in
vitro in the presence of autologous serum as a control or autologous blister
fluid that was obtained from day 3 MT. Telomerase activity per 500 Ki67 
T cells was measured on day 3. The data are representative of three
experiments performed.Telomerase Inhibition in Memory T Cells by Type I Interferon In Vivo 1440
Next, we examined the capacity of CD4  T cells that
were removed from the skin microenvironment to expand
in response to repeated stimulation with PPD stimulation
in vitro (Fig. 6 e). These cells were able to expand in cul-
ture, and this was associated with their ability to up-regu-
late telomerase after restimulation in vitro (Fig. 6 f). How-
ever, despite the optimal stimulation of the skin-derived
CD4  T cells with PPD in vitro, the cells reached replica-
tive senescence at day 125 after eight episodes of restimula-
tion, after which no further expansion of the cells occurred
(Fig. 6 d). This was associated with the loss of telomerase
inducibility in these cells (Fig. 6 e). The loss of telomerase
activity in the repeatedly stimulated cells was not reversed
by the addition of anti–IFN-R2 antibodies (unpublished
data), suggesting that a different mechanism of telomerase
down-regulation was in operation.
Discussion
Most studies on human memory T cell differentia-
tion and proliferation have been performed on peripheral
blood–derived populations, but the actual sites where these
events occur in vivo are poorly defined. To clarify this, we
characterized an experimental system for investigating the
initiation and resolution phases of a human CD4  T cell–
mediated secondary response to antigen in vivo. Using this
model, we demonstrate that there is an increase in PPD-
specific CD4  T cells during the course of this response in
the skin that is largely due to the expansion of T cell clones
that were present early in the response in situ. This is in
contrast with previous studies in mice where Ag-specific T
cell proliferation only occurred in lymphoid, but not in
nonlymphoid, tissues (35–37). These conflicting results
may be due to the fact that we investigated a secondary re-
sponse, whereas the studies in mice related to primary re-
sponses (35, 36).
The intense proliferative activity was accompanied by an
increase in CD4  T cell apoptosis during the course of the
response, indicating that there was extensive T cell turn-
over during this secondary response in the skin. Previous
studies using histological investigation of Mantoux lesions
indicate that the proliferation during this turnover may be
driven in part by the presence of IL-2 and IL-15 within the
skin after PPD injection (5). However, the apoptosis that
was observed was induced by different mechanisms at the
peak and resolution phases of the response (5). Although
the death of the proliferating CD4  T cells at the height of
the response was linked to activation-induced cell death as-
Figure 6. Type I IFN in blister fluid in-
hibits telomerase activity in PPD-stimulated
T cells. IFN- –producing cells present in
day 3 MT skin sections were identified us-
ing indirect alkaline phosphatase staining
(a, top). The bottom panel shows staining
with an isotype control (magnification,
20). Keratinocytes (K) and isolated cells
within the perivascular infiltrates (PV; in-
dicated by arrows) expressed IFN- . (b)
The presence of type I IFN in blister fluid
collected at different times after MT induc-
tion. The data represent the mean   SEM
of type I IFN in blister samples from five
different individuals assayed per time point.
Type I IFN mediates the suppression of
telomerase activity induced by day 3 blister
fluid (c). PBMCs were stimulated with PPD
in vitro in the presence of autologous day 3
blister fluid ( MT BF) or autologous serum
( serum). Blocking antibody reactive with
type I IFN receptor 2 (CD118;  anti-IFN
R) or isotype control antibody ( cnt Ab)
were added to cultures stimulated in the
presence of MT blister fluid. Samples were
collected 3 d after stimulation, and samples
were adjusted to 500 proliferating Ki67  T
cells per reaction for telomerase analysis
(one out of three representative experiments
is shown). Direct inhibition of telomerase
activity by type I IFN (d). A PPD-specific
CD4  T cell line was restimulated with
PPD in the presence of recombinant IFN- 
(black bars) or Roferon (white bars), a
clinical preparation of IFN-  for 4 d. Samples were adjusted so that telomerase activity was measured in an equivalent number of cycling (Ki67 ) T cells
(one of three representative experiments is shown). Blister-derived CD4  T cells can expand in vitro (e). Cells recovered from a day-19 blister were
stimulated in vitro with PPD-pulsed irradiated autologous PBMCs as APCs. Arrows indicate each point of restimulation in vitro. The asterisks indicate
points when samples were collected to measure telomerase activity. Telomerase activity of CD4  T cells isolated from day 19 blisters decreases with
repeated stimulation in vitro (f). Samples were collected on day 4 after each point of PPD restimulation. Telomerase activity per 500 Ki67  T cells
was determined as before. Stim 4, Stim 8, and Stim 9 indicate the 4th, 8th, and 9th stimulations with PPD and irradiated APCs in vitro.Reed et al. 1441
sociated with elevated expression of CD95L, the apoptosis
during the resolution phase was linked to cytokine starva-
tion associated with down-regulation of the antiapoptotic
molecule Bcl-2 (5). Because  80% of the CD4  T cell
clones that were found 21 d after PPD injection were also
present early in the response at day 7, it is likely that prolif-
eration and death are both occurring within the same anti-
gen-specific T cell population that is responding to PPD
within the skin.
We have made several unexpected observations in this
work. First, the kinetics of the clinical response to PPD in-
jection is different from the kinetics of antigen-specific T
cell infiltration. Although the former peaks at 2–3 d when
very few antigen-specific CD4  T cells are present, the lat-
ter peaks between 7–15 d, when the clinical response is
markedly reduced. The events that lead to the recruitment
of the specific cells require further investigation. A second
new observation was that antigen-specific CD4  T cells
were differentiating within the skin after PPD injection.
This was indicated by the significant proliferation and loss
of CD45RB expression by the responding CD4  T cell
population. The down-regulation of CD45RB by human
CD4  T cells has been previously shown to be associated
with profound changes in the capacity for cytokine secre-
tion (28). The functional changes that accompany the dif-
ferentiation of PPD-specific CD4  T cells in the skin are
currently under investigation.
Telomeres have been shown to erode as cells undergo
extensive proliferation and T cells from elderly individuals
have shorter telomeres than young subjects (15). How-
ever, the extent to which telomeres in memory T cells
erode after a single secondary challenge with antigen is
unknown. Therefore, it is of considerable interest that we
observed an average loss of 400 bp of telomere DNA in
the CD4  T cells that were responding in the skin 3 wk
after the injection of PPD. Because telomeres in human
CD4  T cells have been shown to decrease by an average
of 50 bp/yr, this loss of telomeres was equivalent to that
expected after 8 yr of normal aging in vivo (8, 18). At this
rate of telomere erosion, one prediction would be that
cells that continuously proliferate in the skin would reach
senescence rapidly, where growth arrest occurs because
telomeres are unable to fulfil their protective function (9).
However, the investigation of antigen-specific T cells in
draining and nondraining lymph nodes of telomerase-defi-
cient mice (38) and animals with short telomeres (of
equivalent length to that in humans; reference 12) will be
required to assess directly whether telomere erosion limits
uncontrolled T cell proliferation during secondary re-
sponses in vivo.
The accelerated telomere erosion during the secondary
response in the skin was due in part to the active, but re-
versible, inhibition of telomerase in proliferating T cells by
type I IFN. Immunohistological analysis showed that a
constituent of the type I IFN that was detected at day 3 af-
ter PPD challenge was IFN- . However, IFN-  has also
been shown previously to be present at day 3 during this
response (5). Because all the type I IFNs signal through the
same receptor (39), we do not exclude the possibility that
more than one member of this family of mediators contrib-
utes to telomerase inhibition. Although telomerase activity
in CD4  T cells that were stimulated with PPD in vitro
was substantially inhibited by the addition of type I IFN,
we could not completely inhibit the activity of this enzyme
with these cytokines. Extremely low telomerase activity
that was found in proliferating cells in the skin suggests that
other factors may also contribute to inhibition of this en-
zyme in the antigen-specific cells in vivo.
Although telomerase activity in T cells is inhibited by
type I IFN, it can be up-regulated in some T cells by cyto-
kines such as IL-7 (40). These results clearly demonstrate
that different cytokines may have a profound impact on the
replicative lifespan of T cells. Apart from cytokine-medi-
ated regulation of telomerase, intrinsic down-regulation of
enzymatic activity occurs in T cells that are activated re-
peatedly and may be related to end-stage differentiation (9,
10). Telomerase inhibition by this second pathway is irre-
versible, but senescence in these cells can be bypassed by tel-
omerase transfection (41, 42). The signaling pathways that
lead to telomerase down-regulation after repeated stimula-
tion or after addition of type I IFN are poorly defined but
may involve inhibition of CD28 expression (16), transcrip-
tional regulation, capacity for enzyme translocation from
cytoplasm to the nucleus, and also chromatin remodelling
of the telomerase gene (15). These pathways require further
investigation as they may provide targets for manipulating
the retention or loss of specific T cells in vivo.
In summary, we demonstrate that antigen-specific CD4 
T cells can differentiate extensively outside lymphoid tissue
during a secondary response in humans in vivo. This indi-
cates that it is essential to investigate immune responses
within the context of the tissue where they are taking
place. Although this poses significant constraints on the
study of human immunity, the use of appropriate animal
models, such as telomerase (38) or type I IFNR-deficient
animals (4), will enable the clarification of specific ques-
tions that relate to human T cell differentiation during sec-
ondary responses in vivo.
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